Folliculitis decalvans

Source: Wikipedia, the free encyclopedia.
Folliculitis decalvans
SpecialtyDermatology

Folliculitis decalvans is an

rifampin 300 mg twice daily and clindamycin 300 mg twice daily. This new treatment can be used to control the condition, and tests have indicated that after 3 to 5 months long uninterrupted courses of treatment, many patients have seen limited to no recurrence.[4]

Causes

There is no certainty about the cause of this disorder, but the bacterial species

T-cell receptors. Nonetheless Staphylococcus aureus can by found in almost all patients affected by this disorder, while it is detected in only 20–30% of non-affected people.[5]

As Staphylococcus aureus is not always found in people with folliculitis decalvans, other factors must be present. Through examinations in families it was found that there is a family connection to the occurrences, which leads to the conclusion that there is a genetic predisposition for it; for example, patients with folliculitis decalvans could have a hereditary different opening of the hair follicle that could facilitate the lodging of the bacteria. Immunologically, another possibility is that especially strong intercellular fixation protein ICAM-1 contributes to inflammation with its strong effect of attracting white blood cells such as granulocytes and lymphocytes.

Diagnosis

Management

Some sufferers have found that a daily intake of MSM helps relieve the inflammation and scarring that comes with chronic Folliculitis decalvans.

Epidemiology

This disorder was first described by

alopecias and the name Folliculitis decalvans, that remains current, was introduced. About 11% of the occurrences of scarring alopecias are of this type. Men are more commonly affected than women and its appearance is usually between the late teens and middle adult years. According to studies in the United States, African Americans are more frequently affected than White Americans.[citation needed
]

See also

  • Cicatricial alopecia

References

External links